
## Jeffrey Lipman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5251153/publications.pdf Version: 2024-02-01



IFFEDEV LIDMAN

#	Article	IF	CITATIONS
1	International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA - Journal of the American Medical Association, 2009, 302, 2323.	7.4	2,682
2	Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. New England Journal of Medicine, 2012, 367, 1901-1911.	27.0	1,460
3	Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respiratory Medicine,the, 2014, 2, 380-386.	10.7	864
4	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	5.8	843
5	Pharmacokinetic issues for antibiotics in the critically ill patient. Critical Care Medicine, 2009, 37, 840-851.	0.9	755
6	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	9.1	745
7	Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Medicine, 2004, 30, 589-596.	8.2	392
8	Subtherapeutic Initial Î <sup>2</sup> -Lactam Concentrations in Select Critically Ill Patients. Chest, 2012, 142, 30-39.	0.8	354
9	The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents. Advanced Drug Delivery Reviews, 2014, 77, 3-11.	13.7	351
10	Principles of antibacterial dosing in continuous renal replacement therapy. Critical Care Medicine, 2009, 37, 2268-2282.	0.9	335
11	The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients. Clinical Pharmacokinetics, 2011, 50, 99-110.	3.5	325
12	Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Medicine, 2012, 38, 1930-1945.	8.2	322
13	Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial. Clinical Infectious Diseases, 2013, 56, 236-244.	5.8	317
14	Augmented Renal Clearance. Clinical Pharmacokinetics, 2010, 49, 1-16.	3.5	313
15	Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 681-691.	5.6	308
16	Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. International Journal of Antimicrobial Agents, 2010, 36, 332-339.	2.5	305
17	Antibiotic resistance—What's dosing got to do with it?. Critical Care Medicine, 2008, 36, 2433-2440.	0.9	299
18	Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy, 2009, 64, 142-150.	3.0	294

#	Article	IF	CITATIONS
19	A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine, 2008, 34, 2226-2234.	8.2	289
20	Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infectious Diseases, 2018, 5, ofy313.	0.9	255
21	Antibacterial Dosing in Intensive Care. Clinical Pharmacokinetics, 2006, 45, 755-773.	3.5	247
22	A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*. Critical Care Medicine, 2009, 37, 2071-2078.	0.9	244
23	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Medicine, 2016, 42, 1535-1545.	8.2	244
24	Systemic Inflammatory Response Syndrome, Quick Sequential Organ Function Assessment, and Organ Dysfunction. Chest, 2017, 151, 586-596.	0.8	241
25	Augmented Renal Clearance in the ICU. Critical Care Medicine, 2014, 42, 520-527.	0.9	232
26	The Clinical Relevance of Plasma Protein Binding Changes. Clinical Pharmacokinetics, 2013, 52, 1-8.	3.5	225
27	A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1298-1305.	5.6	206
28	Vancomycin Dosing in Critically III Patients: Robust Methods for Improved Continuous-Infusion Regimens. Antimicrobial Agents and Chemotherapy, 2011, 55, 2704-2709.	3.2	197
29	Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Medicine, 2013, 39, 2070-2082.	8.2	192
30	Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infectious Diseases, The, 2009, 9, 245-255.	9.1	185
31	Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy. Critical Care Medicine, 2012, 40, 1523-1528.	0.9	185
32	Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?. Antimicrobial Agents and Chemotherapy, 2013, 57, 6165-6170.	3.2	185
33	An international, multicentre survey of Â-lactam antibiotic therapeutic drug monitoring practice in intensive care units. Journal of Antimicrobial Chemotherapy, 2014, 69, 1416-1423.	3.0	185
34	A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Critical Care, 2011, 15, R139.	5.8	174
35	Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2039-2043.	2.3	172
36	The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. Journal of Antimicrobial Chemotherapy, 2001, 47, 421-429.	3.0	171

#	Article	IF	CITATIONS
37	The Impact of Hospital and ICU Organizational Factors on Outcome in Critically Ill Patients. Critical Care Medicine, 2015, 43, 519-526.	0.9	170
38	Implications of augmented renal clearance in critically ill patients. Nature Reviews Nephrology, 2011, 7, 539-543.	9.6	169
39	A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. Clinical Infectious Diseases, 2016, 62, 1009-1017.	5.8	168
40	Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?. Critical Care Medicine, 2009, 37, 926-933.	0.9	166
41	Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. Critical Care, 2013, 17, R84.	5.8	166
42	A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically III Patients: Discovery and Validation in Independent Cohorts. PLoS Medicine, 2015, 12, e1001916.	8.4	163
43	Continuous infusion of $\hat{l}^2$ -lactam antibiotics in severe infections: a review of its role. International Journal of Antimicrobial Agents, 2007, 30, 11-18.	2.5	161
44	First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents, 2010, 35, 156-163.	2.5	154
45	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Medicine, 2016, 42, 1958-1969.	8.2	151
46	Hydrocortisone and Tumor Necrosis Factor in Severe Community-Acquired Pneumonia. Chest, 1993, 104, 389-392.	0.8	150
47	Does Beta-lactam Pharmacokinetic Variability in Critically III Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Annals of Intensive Care, 2012, 2, 35.	4.6	149
48	Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Critical Care, 2013, 17, R35.	5.8	149
49	Risk factors for target non-attainment during empirical treatment with $\hat{I}^2$ -lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	8.2	147
50	Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the Intensive Care Unit: results from the EPIC II study. International Journal of Antimicrobial Agents, 2011, 38, 331-335.	2.5	145
51	Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Critical Care, 2011, 15, R149.	5.8	141
52	Toward Improved Surveillance: The Impact of Ventilator-Associated Complications on Length of Stay and Antibiotic Use in Patients in Intensive Care Units. Clinical Infectious Diseases, 2013, 56, 471-477.	5.8	141
53	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 136-153.	2.1	134
54	A prospective randomized study comparing once- versos twice-daily amikadn dosing in critically ill adult and paediatric patients. Journal of Antimicrobial Chemotherapy, 1991, 28, 753-764.	3.0	132

#	Article	IF	CITATIONS
55	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	3.0	129
56	On-Site Therapeutic Drug Monitoring. Trends in Biotechnology, 2020, 38, 1262-1277.	9.3	128
57	Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. Journal of Antimicrobial Chemotherapy, 2018, 73, 3087-3094.	3.0	124
58	Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2005, 49, 4814-4815.	3.2	122
59	Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 227-231.	3.0	119
60	Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically III with Severe Sepsis and Septic Shock. Critical Care Clinics, 2011, 27, 19-34.	2.6	118
61	A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. BMC Infectious Diseases, 2015, 15, 3.	2.9	118
62	Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?: FigureÂ1 Journal of Antimicrobial Chemotherapy, 2015, 70, dkv201.	3.0	118
63	A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. New England Journal of Medicine, 2019, 381, 328-337.	27.0	117
64	Low Plasma Cefepime Levels in Critically III Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing. Antimicrobial Agents and Chemotherapy, 1999, 43, 2559-2561.	3.2	115
65	ls continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy, 2006, 59, 285-291.	3.0	111
66	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. Critical Care, 2015, 19, 28.	5.8	111
67	Pharmacological Principles of Antibiotic Prescription in the Critically III. Anaesthesia and Intensive Care, 2002, 30, 134-144.	0.7	109
68	A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care, 2015, 19, 84.	5.8	108
69	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	5.8	108
70	A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 907, 178-184.	2.3	107
71	The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. Journal of Antimicrobial Chemotherapy, 2015, 70, 2671-2677.	3.0	106
72	What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clinical Pharmacokinetics, 2019, 58, 1407-1443.	3.5	106

#	Article	IF	CITATIONS
73	Augmented Creatinine Clearance in Traumatic Brain Injury. Anesthesia and Analgesia, 2010, 111, 1505-1510.	2.2	105
74	Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. British Journal of Clinical Pharmacology, 2004, 58, 259-268.	2.4	104
75	The Impact of Variation in Renal Replacement Therapy Settings on Piperacillin, Meropenem, and Vancomycin Drug Clearance in the Critically III. Critical Care Medicine, 2014, 42, 1640-1650.	0.9	103
76	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	8.2	103
77	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeSâ€, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Medicine, 2019, 45, 1703-1717.	8.2	103
78	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. Journal of Antimicrobial Chemotherapy, 2010, 65, 1771-1778.	3.0	102
79	Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 1999, 43, 309-311.	3.0	101
80	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Medicine, 2018, 44, 189-196.	8.2	101
81	Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Review of Clinical Pharmacology, 2016, 9, 961-979.	3.1	98
82	Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. Journal of Antimicrobial Chemotherapy, 2006, 58, 987-993.	3.0	96
83	Increased fluid resuscitation can lead to adverse outcomes in major-burn injured patients, but low mortality is achievable. Burns, 2008, 34, 1090-1097.	1.9	96
84	Assays for therapeutic drug monitoring of β-lactam antibiotics: A structured review. International Journal of Antimicrobial Agents, 2015, 46, 367-375.	2.5	95
85	Vancomycin-Associated Nephrotoxicity in the Critically III. Critical Care Medicine, 2014, 42, 2527-2536.	0.9	94
86	Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. International Journal of Antimicrobial Agents, 2016, 47, 259-268.	2.5	94
87	Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Current Opinion in Critical Care, 2008, 14, 390-396.	3.2	90
88	Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. BMC Infectious Diseases, 2014, 14, 420.	2.9	88
89	Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis. Antimicrobial Agents and Chemotherapy, 1998, 42, 2235-2239.	3.2	87
90	Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). Journal of Antimicrobial Chemotherapy, 2010, 65, 1276-1285.	3.0	87

#	Article	IF	CITATIONS
91	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Critical Care, 2014, 18, 565.	5.8	87
92	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	5.8	87
93	Intermittent bolus dosing of ceftazidime in critically ill patients. Journal of Antimicrobial Chemotherapy, 1997, 40, 269-273.	3.0	86
94	Improving antibiotic dosing in special situations in the ICU. Current Opinion in Critical Care, 2012, 18, 460-471.	3.2	86
95	Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Medicine, 2020, 46, 225-235.	8.2	86
96	Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Annals of Intensive Care, 2012, 2, 37.	4.6	85
97	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically III Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	5.8	85
98	What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. International Journal of Antimicrobial Agents, 2012, 39, 455-457.	2.5	84
99	How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. BMC Infectious Diseases, 2014, 14, 288.	2.9	83
100	Cefepime Versus Cefpirome: The Importance of Creatinine Clearance. Anesthesia and Analgesia, 2003, 97, 1149-1154.	2.2	81
101	Augmented renal clearance in the Intensive Care Unit: an illustrative case series. International Journal of Antimicrobial Agents, 2010, 35, 606-608.	2.5	81
102	Optimal Doripenem Dosing Simulations in Critically Ill Nosocomial Pneumonia Patients With Obesity, Augmented Renal Clearance, and Decreased Bacterial Susceptibility*. Critical Care Medicine, 2013, 41, 489-495.	0.9	81
103	The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. Journal of Antimicrobial Chemotherapy, 1991, 27, 81-89.	3.0	80
104	A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?. Journal of Antimicrobial Chemotherapy, 2009, 64, 929-937.	3.0	80
105	Antibiotic Dosing in Multiple Organ Dysfunction Syndrome. Chest, 2011, 139, 1210-1220.	0.8	80
106	Identification of Novel Vaccine Candidates against Multidrug-Resistant Acinetobacter baumannii. PLoS ONE, 2013, 8, e77631.	2.5	80
107	Association between augmented renal clearance and clinical outcomes in patients receiving Î <sup>2</sup> -lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. International Journal of Antimicrobial Agents, 2017, 49, 624-630.	2.5	80
108	Patient and family engagement in the ICU: Report from the task force of the World Federation of Societies of Intensive and Critical Care Medicine. Journal of Critical Care, 2018, 48, 251-256.	2.2	76

#	Article	IF	CITATIONS
109	Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Current Opinion in Critical Care, 2015, 21, 412-420.	3.2	75
110	βâ€ <scp>L</scp> actam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 489-496.	1.9	74
111	A randomised controlled study of the efficacy of hypromellose and Lacri-Lube combination versus polyethylene/Cling wrap to prevent corneal epithelial breakdown in the semiconscious intensive care patient. Intensive Care Medicine, 2004, 30, 1122-1126.	8.2	73
112	Autonomic dysfunction in severe tetanus. Critical Care Medicine, 1987, 15, 987-988.	0.9	71
113	Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Medicine, 2001, 27, 363-370.	8.2	69
114	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Internal Medicine Journal, 2011, 41, 537-543.	0.8	69
115	Pulmonary infections complicating ARDS. Intensive Care Medicine, 2020, 46, 2168-2183.	8.2	69
116	Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?. International Journal of Antimicrobial Agents, 2010, 35, 419-420.	2.5	68
117	Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery. Antimicrobial Agents and Chemotherapy, 2011, 55, 5238-5242.	3.2	68
118	Molecular Analysis of the Acinetobacter baumannii Biofilm-Associated Protein. Applied and Environmental Microbiology, 2013, 79, 6535-6543.	3.1	68
119	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. Diagnostic Microbiology and Infectious Disease, 2015, 82, 92-103.	1.8	68
120	Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents, 2019, 53, 211-224.	2.5	68
121	Meropenem Dosing in Critically III Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2010, 54, 2974-2978.	3.2	67
122	Does severe non-infectious SIRS differ from severe sepsis?. Intensive Care Medicine, 2008, 34, 1654-1661.	8.2	66
123	Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically III Patients with Acute Kidney Injury. Antimicrobial Agents and Chemotherapy, 2010, 54, 3635-3640.	3.2	65
124	Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1017-1031.	3.3	65
125	Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients—A One-Year Prospective Study. Therapeutic Drug Monitoring, 2012, 34, 160-164.	2.0	65
126	β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. International Journal of Antimicrobial Agents, 2013, 41, 162-166.	2.5	65

#	Article	IF	CITATIONS
127	Changes in Vancomycin Pharmacokinetics in Critically III Infants. Anaesthesia and Intensive Care, 1995, 23, 678-682.	0.7	64
128	Principles of Antibacterial Dosing in Continuous Renal Replacement Therapy. Blood Purification, 2010, 30, 195-212.	1.8	64
129	Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. Critical Care, 2014, 18, 657.	5.8	64
130	Understanding PK/PD. Intensive Care Medicine, 2016, 42, 1797-1800.	8.2	64
131	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International Journal of Antimicrobial Agents, 2013, 42, 289-293.	2.5	63
132	Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270.	3.6	63
133	How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. International Journal of Antimicrobial Agents, 2012, 39, 187-192.	2.5	62
134	CAMERA2 – combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials, 2016, 17, 170.	1.6	61
135	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1495-1502.	3.0	60
136	Population Pharmacokinetics of Fosfomycin in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6471-6476.	3.2	59
137	Low mannose-binding lectin function is associated with sepsis in adult patients. FEMS Immunology and Medical Microbiology, 2006, 48, 274-282.	2.7	58
138	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clinical Microbiology and Infection, 2017, 23, 533-541.	6.0	58
139	Initial antimicrobial management of sepsis. Critical Care, 2021, 25, 307.	5.8	58
140	Burn Resuscitation—Hourly Urine Output Versus Alternative Endpoints. Shock, 2014, 42, 295-306.	2.1	57
141	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	1.6	57
142	Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. International Journal of Antimicrobial Agents, 2015, 46, 249-253.	2.5	56
143	Serum Procalcitonin and C-reactive Protein as Markers of Sepsis and Outcome in Patients with Neurotrauma and Subarachnoid Haemorrhage. Anaesthesia and Intensive Care, 2004, 32, 465-470.	0.7	55
144	Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. International Journal of Antimicrobial Agents, 2009, 33, 554.e1-554.e7.	2.5	55

#	Article	IF	CITATIONS
145	Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. Critical Care Medicine, 2017, 45, 331-336.	0.9	55
146	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	54
147	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Medicine, 2020, 46, 1404-1417.	8.2	54
148	Vasoconstrictor Effects of Adrenaline in Human Septic Shock. Anaesthesia and Intensive Care, 1991, 19, 61-65.	0.7	53
149	Characteristics of bloodstream infections in burn patients: An 11-year retrospective study. Burns, 2012, 38, 685-690.	1.9	53
150	Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients. International Journal of Antimicrobial Agents, 2013, 42, 384-389.	2.5	53
151	A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2859-2865.	3.0	52
152	Impact of Î <sup>2</sup> -lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. International Journal of Antimicrobial Agents, 2017, 49, 589-594.	2.5	52
153	Challenges in the management of septic shock: a narrative review. Intensive Care Medicine, 2019, 45, 420-433.	8.2	52
154	Cerebrospinal Fluid Penetration of High Doses of Intravenous Ciprofloxacin in Meningitis. Clinical Infectious Diseases, 2000, 31, 1131-1133.	5.8	51
155	Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. International Journal of Antimicrobial Agents, 2005, 26, 50-55.	2.5	51
156	Inter observer variability of the transcranial Doppler ultrasound technique: impact of lack of practice on the accuracy of measurement. Journal of Clinical Monitoring and Computing, 1999, 15, 179-184.	1.6	50
157	The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?. Diagnostic Microbiology and Infectious Disease, 2014, 79, 77-84.	1.8	50
158	Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. International Journal of Antimicrobial Agents, 2015, 45, 41-45.	2.5	50
159	High-Dose Adrenaline in Adult In-Hospital Asystolic Cardiopulmonary Resuscitation: A Double-Blind Randomised Trial. Anaesthesia and Intensive Care, 1993, 21, 192-196.	0.7	49
160	The Costs of Caring for Patients in a Tertiary Referral Australian Intensive Care Unit. Anaesthesia and Intensive Care, 2005, 33, 477-482.	0.7	49
161	Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Medicine, 2009, 35, 2141-2145.	8.2	49
162	Pharmacokinetics and pharmacodynamics in critically ill patients. Current Opinion in Anaesthesiology, 2010, 23, 472-478.	2.0	49

#	Article	IF	CITATIONS
163	Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance. Journal of Neurotrauma, 2017, 34, 137-144.	3.4	49
164	Population Pharmacokinetics of Fluconazole in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration: Using Monte Carlo Simulations To Predict Doses for Specified Pharmacodynamic Targets. Antimicrobial Agents and Chemotherapy, 2011, 55, 5868-5873.	3.2	48
165	Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 2600-2608.	3.0	48
166	A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations. BMC Nephrology, 2013, 14, 250.	1.8	48
167	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	2.5	48
168	Individualising Therapy to Minimize Bacterial Multidrug Resistance. Drugs, 2018, 78, 621-641.	10.9	48
169	Poor discriminatory performance of the Pediatric Risk of Mortality (PRISM) score in a South African intensive care unit. Critical Care Medicine, 1996, 24, 1507-1513.	0.9	48
170	Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Medicine, 2001, 27, 665-672.	8.2	47
171	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases, 2012, 12, 152.	2.9	47
172	Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. International Journal of Antimicrobial Agents, 2012, 39, 69-72.	2.5	47
173	Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. International Journal of Antimicrobial Agents, 2014, 44, 409-415.	2.5	47
174	The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: An appraisal utilizing antibiotics. Advanced Drug Delivery Reviews, 2018, 123, 65-74.	13.7	46
175	Septic Shock: Does Adrenaline have a Role as a First-line Inotropic Agent?. Anaesthesia and Intensive Care, 1992, 20, 470-474.	0.7	45
176	Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. International Journal of Antimicrobial Agents, 2012, 39, 1-10.	2.5	45
177	Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2014, 43, 343-348.	2.5	45
178	Factors Associated with Vancomycin Nephrotoxicity in the Critically III. Anaesthesia and Intensive Care, 2015, 43, 594-599.	0.7	45
179	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. Bioanalysis, 2015, 7, 2585-2595.	1.5	45
180	New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4750-4756.	3.2	45

#	Article	IF	CITATIONS
181	Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review. International Journal of Antimicrobial Agents, 2019, 53, 234-245.	2.5	45
182	The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltrationAn in vitro study of levofloxacin. International Journal of Antimicrobial Agents, 2004, 24, 468-472.	2.5	44
183	Control of an Outbreak of Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Australia after Introduction of Environmental Cleaning with a Commercial Oxidizing Disinfectant. Infection Control and Hospital Epidemiology, 2010, 31, 418-420.	1.8	44
184	Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?. International Journal of Antimicrobial Agents, 2013, 41, 564-568.	2.5	44
185	Candida Colonization as a Risk Marker for Invasive Candidiasis in Mixed Medical-Surgical Intensive Care Units: Development and Evaluation of a Simple, Standard Protocol. Journal of Clinical Microbiology, 2015, 53, 1324-1330.	3.9	44
186	Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiology, 2011, 11, 3.	1.8	43
187	Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. Journal of Antimicrobial Chemotherapy, 2019, 74, 432-441.	3.0	43
188	Predictors of Mortality in Severe Malaria: A Two-Year Experience in a Non-Endemic Area. Anaesthesia and Intensive Care, 1996, 24, 217-223.	0.7	42
189	Severity Scores in Emergency Department Patients With Presumed Infection. Critical Care Medicine, 2016, 44, 539-547.	0.9	42
190	Population Pharmacokinetics of Tigecycline in Critically III Patients with Severe Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	42
191	Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i> , <i>Morganella morganii</i> , <i>Providencia</i> spp, or <i>Serratia marcescens</i> : A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infectious Diseases, 2021, 8, ofab387.	0.9	42
192	Maximally effective dosing regimens of meropenem in patients with septic shock. Journal of Antimicrobial Chemotherapy, 2018, 73, 191-198.	3.0	40
193	Catheter related infection. A plea for consensus with review and guidelines. Intensive Care Medicine, 1988, 14, 503-509.	8.2	39
194	Subcutaneous oxygen tensions provide similar information to ileal luminal CO2 tensions in an animal model of haemorrhagic shock. Intensive Care Medicine, 2000, 26, 592-600.	8.2	39
195	Lateral positioning of ventilated intensive care patients: A study of oxygenation, respiratory mechanics, hemodynamics, and adverse events. Heart and Lung: Journal of Acute and Critical Care, 2007, 36, 277-286.	1.6	39
196	Do We Understand the Impact of Altered Physiology, Consequent Interventions and Resultant Clinical Scenarios in the Intensive Care Unit? the Antibiotic Story. Anaesthesia and Intensive Care, 2011, 39, 999-1000.	0.7	39
197	Antibiotic dose optimization in critically ill patients. Medicina Intensiva, 2015, 39, 563-572.	0.7	39
198	When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit. Clinical Microbiology and Infection, 2020, 26, 35-40.	6.0	39

#	Article	IF	CITATIONS
199	Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?. Intensive Care Medicine, 2002, 28, 493-500.	8.2	38
200	Point of care measurement of plasma creatinine in critically ill patients with acute kidney injury. Anaesthesia, 2009, 64, 403-407.	3.8	38
201	Antimicrobial chemotherapy and lung microdialysis: a review. International Journal of Antimicrobial Agents, 2010, 36, 491-500.	2.5	38
202	ARC - Augmented Renal Clearance. Current Pharmaceutical Biotechnology, 2011, 12, 2020-2029.	1.6	38
203	Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. Journal of Neurosurgery, 2013, 118, 297-301.	1.6	38
204	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4577-4584.	3.2	38
205	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 6550-6557.	3.2	38
206	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy, 2016, 71, 2509-2520.	3.0	38
207	Intravenous calcium chloride as an antidote to verapamil-induced hypotension. Intensive Care Medicine, 1982, 8, 55-57.	8.2	37
208	Can We Achieve Consensus on Central Venous Catheter-Related Infections?. Anaesthesia and Intensive Care, 2000, 28, 475-490.	0.7	37
209	The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Critical Care, 2005, 9, R710.	5.8	37
210	Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy. Antimicrobial Agents and Chemotherapy, 2014, 58, 3533-3537.	3.2	37
211	What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. Journal of Antimicrobial Chemotherapy, 2016, 71, 696-702.	3.0	37
212	Routine Changing of Intravenous Administration Sets Does Not Reduce Colonization or Infection in Central Venous Catheters. Infection Control and Hospital Epidemiology, 2004, 25, 650-655.	1.8	36
213	Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Medicine, 2007, 33, 781-788.	8.2	36
214	Subtleties in practical application of prolonged infusion of β-lactam antibiotics. International Journal of Antimicrobial Agents, 2015, 45, 461-463.	2.5	36
215	Interethnic Differences in Pharmacokinetics of Antibacterials. Clinical Pharmacokinetics, 2015, 54, 243-260.	3.5	36
216	Problematic Dichotomization of Risk for Intensive Care Unit (ICU)–Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients. Clinical Infectious Diseases, 2016, 63, 1463-1469.	5.8	36

#	Article	IF	CITATIONS
217	Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy, 2016, 71, 464-470.	3.0	36
218	Hemoglobin concentrations and RBC transfusion thresholds in patients with acute brain injury: an international survey. Critical Care, 2017, 21, 159.	5.8	36
219	Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Review of Clinical Pharmacology, 2019, 12, 623-634.	3.1	36
220	A New Marker of Sepsis Post Burn Injury?*. Critical Care Medicine, 2014, 42, 2029-2036.	0.9	35
221	The Durban World Congress Ethics Round Table Conference Report: I. Differences between withholding and withdrawing life-sustaining treatments. Journal of Critical Care, 2014, 29, 890-895.	2.2	35
222	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	35
223	β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. Journal of Antimicrobial Chemotherapy, 2020, 75, 429-433.	3.0	35
224	The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Medicine, 2011, 37, 816-823.	8.2	34
225	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	34
226	Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing Enterobacter hormaechei. Nature Communications, 2020, 11, 466.	12.8	34
227	Comparison of disease severity scoring systems in septic shock. Critical Care Medicine, 1991, 19, 1165-1171.	0.9	33
228	Continuous measurement of cerebral blood flow velocity using transcranial Doppler reveals significant moment-to-moment variability of data in healthy volunteers and in patients with subarachnoid hemorrhage*. Critical Care Medicine, 2002, 30, 563-569.	0.9	33
229	High Dependency Units: Issues to Consider in Their Planning. Anaesthesia and Intensive Care, 2002, 30, 348-354.	0.7	33
230	Is the end-game penetration (of the airway)?*. Critical Care Medicine, 2005, 33, 1654-1655.	0.9	33
231	Returning to the pre-antibiotic era in the critically ill: The XDR problem*. Critical Care Medicine, 2007, 35, 1789-1791.	0.9	33
232	Physiological Changes in the Critically Ill Patient with Sepsis. Current Pharmaceutical Biotechnology, 2011, 12, 1991-1995.	1.6	33
233	Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. International Journal of Antimicrobial Agents, 2006, 28, 147-150.	2.5	32
234	The Durban World Congress Ethics Round Table Conference Report: II. Withholding or withdrawing of treatment in elderly patients admitted to the intensive care unit. Journal of Critical Care, 2014, 29, 896-901.	2.2	32

#	Article	IF	CITATIONS
235	The Durban World Congress Ethics Round Table Conference Report: III. Withdrawing Mechanical ventilation—the approach should be individualized. Journal of Critical Care, 2014, 29, 902-907.	2.2	32
236	Caspofungin Population Pharmacokinetics in Critically III Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. Clinical Pharmacokinetics, 2017, 56, 1057-1068.	3.5	32
237	Uncertainty in Antibiotic Dosing in Critically III Neonate and Pediatric Patients: Can Microsampling Provide the Answers?. Clinical Therapeutics, 2016, 38, 1961-1975.	2.5	31
238	Coronary embolism causing myocardial infarction. Intensive Care Medicine, 1990, 16, 215-216.	8.2	30
239	Assessment of peripheral arterial catheters as a source of sepsis in the critically ill: a narrative review. Journal of Hospital Infection, 2010, 75, 12-18.	2.9	30
240	Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. Journal of Antimicrobial Chemotherapy, 2014, 69, 2797-2803.	3.0	30
241	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. International Journal of Antimicrobial Agents, 2016, 48, 542-546.	2.5	30
242	Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. International Journal of Antimicrobial Agents, 2007, 29, 117-128.	2.5	29
243	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy, 2014, 69, 2508-2516.	3.0	29
244	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. Bioanalysis, 2016, 8, 2235-2242.	1.5	29
245	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically III Patients on Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 4901-4909.	3.2	29
246	Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2020, 8, 191.	3.6	29
247	Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. South African Journal of Surgery, 1997, 35, 20-3.	0.2	29
248	Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiologica, 2012, 78, 94-104.	1.0	29
249	The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration. International Journal of Antimicrobial Agents, 2004, 24, 468-472.	2.5	28
250	Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Current Opinion in Critical Care, 2010, 16, 470-474.	3.2	28
251	Antimicrobial Utilisation in 37 Australian and New Zealand Intensive Care Units. Anaesthesia and Intensive Care, 2011, 39, 231-237.	0.7	28
252	To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt. Current Opinion in Pharmacology, 2015, 24, 68-78.	3.5	28

#	Article	IF	CITATIONS
253	Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. International Journal of Antimicrobial Agents, 2015, 46, 39-44.	2.5	28
254	A simple LC–MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 39-45.	2.8	28
255	Acute Preload Effects of Furosemide. Chest, 1990, 98, 124-128.	0.8	27
256	A comparison of arterial lines and insertion techniques in critically ill patients. Anaesthesia, 1994, 49, 968-973.	3.8	27
257	Autonomic dysfunction in tetanus – what lessons can be learnt with specific reference to alphaâ€⊋ agonists?. Anaesthesia, 2007, 62, 1066-1070.	3.8	27
258	Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review. Surgical Infections, 2012, 13, 9-17.	1.4	27
259	Tracheal Cuff Pressure Monitoring in the ICU: A Literature Review and Survey of Current Practice in Queensland. Anaesthesia and Intensive Care, 2014, 42, 761-770.	0.7	27
260	Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. International Journal of Antimicrobial Agents, 2014, 44, 163-167.	2.5	27
261	The Durban World Congress Ethics Round Table IV: Health care professional end-of-life decision making. Journal of Critical Care, 2015, 30, 224-230.	2.2	27
262	<i>Ex Vivo</i> Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	27
263	International facilitators and barriers to family engagement in the ICU: Results of a qualitative analysis. Journal of Critical Care, 2020, 58, 72-77.	2.2	27
264	Do Burn Patients Cost More? The Intensive Care Unit Costs of Burn Patients Compared With Controls Matched for Length of Stay and Acuity. Journal of Burn Care and Research, 2010, 31, 598-602.	0.4	26
265	Select Critically ill Patients at Risk of Augmented Renal Clearance: Experience in a Malaysian Intensive Care, 2014, 42, 715-722.	0.7	26
266	Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 1411-1417.	3.2	26
267	Augmented renal clearance and therapeutic monitoring of β-lactams. International Journal of Antimicrobial Agents, 2015, 45, 331-333.	2.5	26
268	Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiologica, 2014, 80, 1302-9.	1.0	26
269	Disease Risk and Mortality Prediction in Intensive Care Patients with Pneumonia. Australian and New Zealand Practice in Intensive Care (ANZPIC II). Anaesthesia and Intensive Care, 2005, 33, 101-111.	0.7	25
270	The use and risks of antibiotics in critically ill patients. Expert Opinion on Drug Safety, 2016, 15, 667-678.	2.4	25

#	Article	lF	CITATIONS
271	Dosing antibiotic prophylaxis during cardiopulmonary bypass—a higher level of complexity? A structured review. International Journal of Antimicrobial Agents, 2017, 49, 395-402.	2.5	25
272	Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. British Journal of Anaesthesia, 2017, 118, 876-882.	3.4	25
273	Does Furosemide Increase Oxidative Stress in Acute Kidney Injury?. Antioxidants and Redox Signaling, 2017, 26, 221-226.	5.4	25
274	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. Bioanalysis, 2018, 10, 407-423.	1.5	25
275	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. International Journal of Antimicrobial Agents, 2018, 52, 151-157.	2.5	25
276	Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study. Journal of Critical Care, 2019, 52, 75-79.	2.2	25
277	Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?. Minerva Anestesiologica, 2016, 82, 957-65.	1.0	25
278	Gastric intramucosal pH and blood lactate in severe sepsis. Anaesthesia, 1997, 52, 726-732.	3.8	24
279	Positioning practices for ventilated intensive care patients: current practice, indications and contraindications. Australian Critical Care, 2006, 19, 122-132.	1.3	24
280	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. International Journal of Antimicrobial Agents, 2013, 42, 90-93.	2.5	24
281	Infections and Use of Antibiotics in Patients Admitted for Severe Acute Pancreatitis: Data from the EPIC II Study. Surgical Infections, 2014, 15, 394-398.	1.4	24
282	The Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical Trial. PLoS ONE, 2015, 10, e0144740.	2.5	24
283	The Treatment of Tetanus with Intrathecal Baclofen. Anaesthesia and Intensive Care, 2000, 28, 438-442.	0.7	23
284	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC–MS/MS: Application to a pilot pharmacokinetic study in humans. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 509-514.	2.8	23
285	A UHPLC–MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 324-333.	2.8	23
286	The Ecology of Antibiotic Use in the ICU: Homogeneous Prescribing of Cefepime but Not Tazocin Selects for Antibiotic Resistant Infection. PLoS ONE, 2012, 7, e38719.	2.5	23
287	Erythropoietin in a patient following multiple trauma. Anaesthesia, 1992, 47, 962-964.	3.8	22
288	You Only Find what you Look for: The Importance of High Creatinine Clearance in the Critically III. Anaesthesia and Intensive Care, 2009, 37, 11-13.	0.7	22

#	Article	IF	CITATIONS
289	The Value of E-Learning for the Prevention of Healthcare-Associated Infections. Infection Control and Hospital Epidemiology, 2016, 37, 1052-1059.	1.8	22
290	Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study. Critical Care Medicine, 2016, 44, e923-e929.	0.9	22
291	Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. International Journal of Antimicrobial Agents, 2016, 48, 748-752.	2.5	22
292	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLCâ€MS/MS: application to a pilot pharmacokinetic study in humans. Biomedical Chromatography, 2016, 30, 872-879.	1.7	22
293	Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	22
294	Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	22
295	Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?. Clinical Pharmacokinetics, 2018, 57, 439-454.	3.5	22
296	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. Critical Care, 2019, 23, 205.	5.8	22
297	Genomic surveillance, characterization and intervention of a polymicrobial multidrug-resistant outbreak in critical care. Microbial Genomics, 2021, 7, .	2.0	22
298	Management of Invasive Candidiasis in the Intensive Care Unit. Drugs, 2010, 70, 823-839.	10.9	21
299	The Critical Care Costs of the Influenza A/H1N1 2009 Pandemic in Australia and New Zealand. Anaesthesia and Intensive Care, 2011, 39, 384-391.	0.7	21
300	Determining authorship in multicenter trials: a systematic review. Acta Anaesthesiologica Scandinavica, 2011, 55, 1037-1043.	1.6	21
301	Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. Journal of Antimicrobial Chemotherapy, 2015, 70, 528-533.	3.0	21
302	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
303	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	21
304	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	21
305	β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. International Journal of Antimicrobial Agents, 2020, 55, 105839.	2.5	21
306	A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100970.	1.4	21

#	Article	IF	CITATIONS
307	Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing?*. Critical Care Medicine, 2011, 39, 602-603.	0.9	20
308	Remote care by telemedicine in the ICU. Current Opinion in Critical Care, 2011, 17, 634-640.	3.2	20
309	Editorial Commentary: Closing the LoopA Colistin Clinical Study to Confirm Dosing Recommendations From PK/PD Modeling. Clinical Infectious Diseases, 2012, 54, 1727-1729.	5.8	20
310	Low Flucloxacillin Concentrations in a Patient With Central Nervous System Infection. Annals of Pharmacotherapy, 2014, 48, 1380-1384.	1.9	20
311	Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. BMC Infectious Diseases, 2014, 14, 513.	2.9	20
312	Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis. International Journal of Antimicrobial Agents, 2015, 45, 647-651.	2.5	20
313	Is there a role for microsampling in antibiotic pharmacokinetic studies?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 601-614.	3.3	20
314	Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. International Journal of Antimicrobial Agents, 2017, 50, 227-231.	2.5	20
315	A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 4689-4694.	3.2	19
316	Is inhaled prophylactic heparin useful for prevention and Management of Pneumonia in ventilated ICU patients?. Journal of Critical Care, 2016, 34, 95-102.	2.2	19
317	A guideline for competency of the critical care nurse. American Journal of Critical Care, 1996, 5, 217-226.	1.6	19
318	Decreased cardiac index as an indicator of tension pneumothorax in the ventilated patient. Anaesthesia, 1994, 49, 137-141.	3.8	18
319	The Spectrum of Practice in the Diagnosis and Management of Pneumonia in Patients Requiring Mechanical Ventilation. Australian and New Zealand Practice in Intensive Care (ANZPIC II). Anaesthesia and Intensive Care, 2005, 33, 87-100.	0.7	18
320	Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq0 0	0 rgBT /0	verlock 10 Tf
321	Defining Antibiotic Dosing in Lung Infections. Clinical Pulmonary Medicine, 2013, 20, 121-128.	0.3	18
322	Should β-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists. International Journal of Antimicrobial Agents, 2016, 47, 436-438.	2.5	18
323	<i>In Vivo</i> Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. Antimicrobial Agents and Chemotherapy, 2016, 60, 827-832.	3.2	18
324	Defining optimal dosing of ciprofloxacin in patients with septic shock. Journal of Antimicrobial	3.0	18

Chemotherapy, 2019, 74, 1662-1669. 324

#	Article	IF	CITATIONS
325	Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clinical Pharmacokinetics, 2020, 59, 1237-1250.	3.5	18
326	Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. Journal of Antimicrobial Chemotherapy, 2020, 75, 2641-2649.	3.0	18
327	Acute Lung Injury at Baragwanath ICU. Chest, 1993, 103, 1832-1836.	0.8	17
328	Optimizing Use of Î <sup>2</sup> -Lactam Antibiotics in the Critically Ill. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 579-585.	2.1	17
329	Inadequate antimicrobial prophylaxis during surgery: a study of β-lactam levels during burn debridement. Journal of Antimicrobial Chemotherapy, 2007, 60, 166-169.	3.0	17
330	An LC–MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. Bioanalysis, 2017, 9, 911-924.	1.5	17
331	Identifying "at-risk―patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections. Critical Care, 2017, 21, 283.	5.8	17
332	Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	17
333	Strategies to Reduce Inappropriate Laboratory Blood Test Orders in Intensive Care Are Effective and Safe: A Before-And-After Quality Improvement Study. Anaesthesia and Intensive Care, 2018, 46, 313-320.	0.7	17
334	CRITICAL CARE IN AFRICA. Critical Care Clinics, 1997, 13, 255-265.	2.6	16
335	The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 739-744.	2.9	16
336	Seated and semi-recumbent positioning of the ventilated intensive care patient – Effect on gas exchange, respiratory mechanics and hemodynamics. Heart and Lung: Journal of Acute and Critical Care, 2014, 43, 105-111.	1.6	16
337	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 1643-1650.	3.0	16
338	Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. Journal of Antimicrobial Chemotherapy, 2018, 73, 1647-1650.	3.0	16
339	Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. International Journal of Antimicrobial Agents, 2020, 55, 105943.	2.5	16
340	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. Clinical Pharmacokinetics, 2021, 60, 655-664.	3.5	16
341	Evaluation of Meropenemâ€Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically III Patients With Augmented Renal Clearance. Clinical Pharmacology and Therapeutics, 2021, 109, 1104-1115.	4.7	16
342	Continuous infusion of β-lactams in the intensive care unit—Best way to hit the target?*. Critical Care Medicine, 2008, 36, 1663-1664.	0.9	15

#	Article	IF	CITATIONS
343	Review article: Part one: Goalâ€directed resuscitation – Which goals? Haemodynamic targets. EMA - Emergency Medicine Australasia, 2012, 24, 14-22.	1.1	15
344	Epha4-Fc Treatment Reduces Ischemia/Reperfusion-Induced Intestinal Injury by Inhibiting Vascular Permeability. Shock, 2016, 45, 184-191.	2.1	15
345	Factors influencing psychological, social and health outcomes after major burn injuries in adults: cohort study protocol. BMJ Open, 2017, 7, e017545.	1.9	15
346	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically III Patients with an Indwelling External Ventricular Drain. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	15
347	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Annals of Intensive Care, 2021, 11, 49.	4.6	15
348	Fungal infections in critically ill patients. BMJ: British Medical Journal, 1997, 315, 266-267.	2.3	15
349	An international survey of adherence to Surviving Sepsis Campaign Guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock. Journal of Critical Care, 2022, 68, 144-154.	2.2	15
350	Haemodynamic and oxygen transport response during exchange transfusion for severe falciparum malaria. Postgraduate Medical Journal, 1994, 70, 801-804.	1.8	14
351	Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustainedâ€release diltiazem. Anaesthesia, 2008, 63, 714-718.	3.8	14
352	Respiratory Complications in Burns. Clinical Pulmonary Medicine, 2009, 16, 132-138.	0.3	14
353	Pharmacokinetics of Piperacillin in Critically III Australian Indigenous Patients with Severe Sepsis. Antimicrobial Agents and Chemotherapy, 2016, 60, 7402-7406.	3.2	14
354	SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infectious Diseases, 2016, 16, 103.	2.9	14
355	Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270― Microorganisms, 2019, 7, 386.	3.6	14
356	Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion. International Journal of Antimicrobial Agents, 2019, 54, 741-749.	2.5	14
357	Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. International Journal of Antimicrobial Agents, 2019, 53, 137-142.	2.5	14
358	Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy. Frontiers in Medicine, 2020, 7, 588863.	2.6	14
359	Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 415-430.	3.3	14
360	Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. Frontiers in Pharmacology, 2020, 11, 883.	3.5	14

#	Article	IF	CITATIONS
361	Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·mâ^'2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. Anesthesia and Analgesia, 2020, 131, 199-207.	2.2	14
362	The Australian response to the COVID-19 pandemic: A co-ordinated and effective strategy. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100859.	1.4	14
363	Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2012, 14, 312-5.	0.1	14
364	Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study. International Journal of Antimicrobial Agents, 2022, 60, 106591.	2.5	14
365	Difficulty in weaning from respiratory support in a patient with the intermediate syndrome of organophosphate poisoning. Critical Care Medicine, 1989, 17, 1075-1076.	0.9	13
366	The entrapped central venous catheter. British Journal of Anaesthesia, 2007, 98, 89-92.	3.4	13
367	A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis. International Journal of Antimicrobial Agents, 2008, 31, 240-244.	2.5	13
368	Tissue Accumulation of Cephalothin in Burns: a Comparative Study by Microdialysis of Subcutaneous Interstitial Fluid Cephalothin Concentrations in Burn Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2009, 53, 210-215.	3.2	13
369	Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1431-1440.	3.3	13
370	Review article: Part two: Goalâ€directed resuscitation – Which goals? Perfusion targets. EMA - Emergency Medicine Australasia, 2012, 24, 127-135.	1.1	13
371	Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing. Intensive Care Medicine, 2013, 39, 1322-1324.	8.2	13
372	Can We Use an Ex Vivo Continuous Hemofiltration Model to Describe the Adsorption and Elimination of Meropenem and Piperacillin?. International Journal of Artificial Organs, 2015, 38, 419-424.	1.4	13
373	Antibiotic dosing for multidrug-resistant pathogen pneumonia. Current Opinion in Infectious Diseases, 2017, 30, 231-239.	3.1	13
374	Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units. Drugs, 2021, 81, 1065-1078.	10.9	13
375	Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?. Antibiotics, 2020, 9, 51.	3.7	13
376	Use of Antimicrobials for Bloodstream Infections in the Intensive Care Unit, a Clinically Oriented Review. Antibiotics, 2022, 11, 362.	3.7	13
377	Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs. Clinical Microbiology and Infection, 2022, 28, 1211-1224.	6.0	13
378	Intravascular administration sets are accurate and in appropriate condition after 7 days of continuous use: an in vitro study. Journal of Advanced Nursing, 2002, 37, 330-337.	3.3	12

#	Article	IF	CITATIONS
379	Antimicrobial stewardship of β-lactams in intensive care units. Expert Review of Anti-Infective Therapy, 2014, 12, 581-595.	4.4	12
380	Integrated pharmacokinetic–pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. Journal of Antimicrobial Chemotherapy, 2016, 71, 2902-2908.	3.0	12
381	Characteristics, treatment and outcomes for all emergency department patients fulfilling criteria for septic shock: a prospective observational study. European Journal of Emergency Medicine, 2018, 25, 97-104.	1.1	12
382	Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol. BMJ Open, 2017, 7, e016747.	1.9	12
383	Prevalence of Augmented Renal Clearance and Performance of Glomerular Filtration Estimates in Indigenous Australian Patients Requiring Intensive Care Admission. Anaesthesia and Intensive Care, 2018, 46, 42-50.	0.7	12
384	New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 693-708.	3.3	12
385	The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 637-647.	2.9	12
386	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 169, 288-292.	2.8	12
387	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2020, 75, 2633-2640.	3.0	12
388	Predictors of Physician Confidence to Diagnose Pneumonia and Determine Illness Severity in Ventilated Patients. Australian and New Zealand Practice in Intensive Care (ANZPIC II). Anaesthesia and Intensive Care, 2005, 33, 112-119.	0.7	11
389	Successful use of continuous venoâ€venous haemofiltration to treat profound fluid retention in severe peripartum cardiomyopathy. Anaesthesia, 1993, 48, 1065-1067.	3.8	11
390	Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial. BMJ Open, 2011, 1, e000334-e000334.	1.9	11
391	A national survey of renal replacement therapy prescribing practice for acute kidney injury in <scp>M</scp> alaysian intensive care units. Nephrology, 2014, 19, 507-512.	1.6	11
392	Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (Stab Study). Peritoneal Dialysis International, 2016, 36, 421-426.	2.3	11
393	Population Pharmacokinetics of Doripenem in Critically III Patients with Sepsis in a Malaysian Intensive Care Unit. Antimicrobial Agents and Chemotherapy, 2016, 60, 206-214.	3.2	11
394	A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. Analytical and Bioanalytical Chemistry, 2019, 411, 7831-7840.	3.7	11
395	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. Clinical Pharmacokinetics, 2020, 59, 1027-1036.	3.5	11
396	Fatal infection caused by a multiply resistant type 3 pneumococcus. Journal of Clinical Microbiology, 1988, 26, 1590-1591.	3.9	11

#	Article	IF	CITATIONS
397	Multiple organ failure after trauma. BMJ: British Medical Journal, 1996, 313, 573-574.	2.3	11
398	Critical care research and pre-emptive informed consent: a practical approach used in chris hani baragwanath ICU. Intensive Care Medicine, 1998, 24, 353-357.	8.2	10
399	Paralytic ileus as a complication of atropine therapy following severe organophosphate poisoning. Anaesthesia, 2007, 49, 791-793.	3.8	10
400	Airway Obstruction due to a Pre-vertebral Haematoma following Difficult Central Line Insertion – Implications for Ultrasound Guidance and Review of the Literature. Anaesthesia and Intensive Care, 2009, 37, 309-313.	0.7	10
401	How should we dose antibiotics for pneumonia in the ICU?. Current Opinion in Infectious Diseases, 2013, 26, 189-195.	3.1	10
402	Antibiotic dosing in obesity: a BIG challenge. Critical Care, 2016, 20, 240.	5.8	10
403	An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. Pharmaceutical Research, 2020, 37, 96.	3.5	10
404	Optimising Treatment Outcomes for Children and Adults Through Rapid Genome Sequencing of Sepsis Pathogens. A Study Protocol for a Prospective, Multi-Centre Trial (DIRECT). Frontiers in Cellular and Infection Microbiology, 2021, 11, 667680.	3.9	10
405	Early Sequential Microcirculation Assessment in Shocked Patients as a Predictor of Outcome. Shock, 2020, Publish Ahead of Print, 581-586.	2.1	10
406	Pharmacodynamics of ceftriaxone for the treatment of methicillinâ€susceptible Staphylococcus aureus: is it a viable treatment option?. International Journal of Antimicrobial Agents, 2022, 59, 106537.	2.5	10
407	A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 63-68.	0.1	10
408	Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. BMC Nephrology, 2009, 10, 42.	1.8	9
409	A prospective registry of emergency department patients admitted with infection. BMC Infectious Diseases, 2011, 11, 27.	2.9	9
410	A Comparison of Pulse Contour Wave Analysis and Ultrasonic Cardiac Output Monitoring in the Critically III. Anaesthesia and Intensive Care, 2012, 40, 631-637.	0.7	9
411	An UHPLC–MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. Bioanalysis, 2015, 7, 2311-2319.	1.5	9
412	A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically III Patients with Uninflamed Meninges. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	9
413	Optimised Dosing of Vancomycin in Critically III Indigenous Australian Patients with Severe Sepsis. Anaesthesia and Intensive Care, 2018, 46, 374-380.	0.7	9
414	Subtleties of antibiotic dosagesdo doses and intervals make a difference in the critically ill?. South African Journal of Surgery, 1996, 34, 160-2.	0.2	9

#	Article	IF	CITATIONS
415	Pitfalls in the prediction of renal function in the intensive care unit. A review. South African Journal of Surgery, 1997, 35, 16-9.	0.2	9
416	Esmolol in a case of severe tetanus. Adequate haemodynamic control achieved despite markedly elevated catecholamine levels. South African Journal of Surgery, 1994, 32, 33-5.	0.2	9
417	The implications of enterococci for the intensive care unit. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2007, 9, 69-75.	0.1	9
418	Intensive Care Utilisation: The Baragwanath Experience. Anaesthesia and Intensive Care, 1993, 21, 396-399.	0.7	8
419	Unbound Cephalothin Pharmacokinetics in Adult Burn Patients Are Related to the Elapsed Time after Injury. Antimicrobial Agents and Chemotherapy, 2009, 53, 5303-5305.	3.2	8
420	Prior Statin Use Is Not Associated With Improved Outcome in Emergency Patients Admitted With Infection: A Prospective Observational Study. Academic Emergency Medicine, 2011, 18, 127-134.	1.8	8
421	Variable ganciclovir concentrations in a critically ill patient receiving continuous renal replacement therapy and plasma exchange?. International Journal of Antimicrobial Agents, 2014, 43, 570-571.	2.5	8
422	Pharmacokinetics of fluconazole in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. International Journal of Antimicrobial Agents, 2015, 45, 192-195.	2.5	8
423	Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring. Infectious Diseases, 2015, 47, 739-742.	2.8	8
424	Therapeutic targets in necrotizing soft tissue infections. Intensive Care Medicine, 2017, 43, 1717-1719.	8.2	8
425	What's new in pharmacokinetics of antimicrobials in AKI and RRT?. Intensive Care Medicine, 2017, 43, 904-906.	8.2	8
426	Utility of communityâ€acquired pneumonia severity scores in guiding disposition from the emergency department: Intensive care or shortâ€stay unit?. EMA - Emergency Medicine Australasia, 2018, 30, 538-546.	1.1	8
427	Vena Cava filters in severely-injured patients: One size does not fit all. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 305-307.	1.4	8
428	Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. Journal of Infection and Chemotherapy, 2019, 25, 503-508.	1.7	8
429	Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. Clinical Chemistry and Laboratory Medicine, 2020, 58, 274-284.	2.3	8
430	Pitfalls in the interpretation of pulmonary capillary wedge pressure. South African Medical Journal, 1985, 67, 174-7.	0.6	8
431	A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2010, 12, 162-70.	0.1	8
432	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, e0218921.	3.2	8

#	Article	IF	CITATIONS
433	A Double-blind Comparison of Vecuronium Administered by the Springfusor® Infusion Device to Vecuronium by Intermittent Bolus Injection in Critically III Adult Patients. Anaesthesia and Intensive Care, 1994, 22, 580-585.	0.7	7
434	Acute respiratory distress syndrome precipitated by transjugular intrahepatic porto-systemic shunting for severe hepatic veno-occlusive disease. Is it due to pulmonary leucostasis?. Intensive Care Medicine, 1999, 25, 1332-1333.	8.2	7
435	Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2011, 37, 90-92.	2.5	7
436	Experience with High Frequency Oscillation Ventilation during the 2009 H1N1 Influenza Pandemic in Australia and New Zealand. Anaesthesia and Intensive Care, 2011, 39, 837-846.	0.7	7
437	The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. BMC Anesthesiology, 2011, 11, 5.	1.8	7
438	Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2016, 36, 415-420.	2.3	7
439	A comparison between raw and predicted mortality in a paediatric intensive care unit in South Africa. BMC Research Notes, 2018, 11, 829.	1.4	7
440	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. Intensive Care Medicine Experimental, 2018, 6, 17.	1.9	7
441	A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2018, 52, 506-509.	2.5	7
442	In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. International Journal of Antimicrobial Agents, 2019, 54, 261-264.	2.5	7
443	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). Therapeutic Drug Monitoring, 2019, 41, 703-713.	2.0	7
444	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
445	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. Analytical and Bioanalytical Chemistry, 2022, 414, 2155-2162.	3.7	7
446	A new paradigm for treating infections: "go hard and go home". Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2009, 11, 276-81.	0.1	7
447	Vitamin B12 levels in the prolonged use of sodium nitroprusside. Critical Care Medicine, 1984, 12, 161-163.	0.9	6
448	Small tidal volume ventilation using a zero deadspace tracheal tube. British Journal of Anaesthesia, 1999, 82, 213-216.	3.4	6
449	Manual hyperinflation causes norepinephrine release. Heart and Lung: Journal of Acute and Critical Care, 2006, 35, 262-268.	1.6	6
450	Predictors and Outcome Associated with an Enterococcus Positive Isolate during Intensive Care Unit Admission. Anaesthesia and Intensive Care, 2009, 37, 976-982.	0.7	6

#	Article	IF	CITATIONS
451	Tissue Distribution of Betaâ€Lactam Antibiotics: Continuous versus Bolus Dosing. Journal of Pharmacy Practice and Research, 2009, 39, 219-222.	0.8	6
452	Does Appropriate Antibiotic Therapy Mean Only Adequate Spectrum and Timing?*. Critical Care Medicine, 2015, 43, 1773-1774.	0.9	6
453	Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. International Journal of Antimicrobial Agents, 2015, 46, 121-124.	2.5	6
454	We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?. Critical Care, 2016, 20, 163.	5.8	6
455	"Salvage treatment―for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. Intensive Care Medicine, 2017, 43, 1164-1166.	8.2	6
456	Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. Antibiotics, 2020, 9, 793.	3.7	6
457	Microsampling to support pharmacokinetic clinical studies in pediatrics. Pediatric Research, 2022, 91, 1557-1561.	2.3	6
458	Typhoid Fever: An Undescribed Cause of Adult Respiratory Distress Syndrome. Anaesthesia and Intensive Care, 1991, 19, 124-126.	0.7	5
459	Acute stridor as a presentation of bilateral abductor vocal cord paralysis. Anaesthesia, 1996, 51, 1046-1048.	3.8	5
460	Making the wrong choice: Consequences for patients with infections due to methicillin-resistant Staphylococcus aureus*. Critical Care Medicine, 2006, 34, 2239-2241.	0.9	5
461	Resistance in the intensive care unit: Whose problem is it and how can intensivists help?*. Critical Care Medicine, 2007, 35, 299-301.	0.9	5
462	Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. International Journal of Antimicrobial Agents, 2009, 34, 383-384.	2.5	5
463	Phenytoin Loading Doses in Adult Critical Care Patients: Does Current Practice Achieve Adequate Drug Levels?. Anaesthesia and Intensive Care, 2013, 41, 602-609.	0.7	5
464	Anaesthetic Management of Obese Parturients: What is the Evidence Supporting Practice Guidelines?. Anaesthesia and Intensive Care, 2016, 44, 552-559.	0.7	5
465	Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. Journal of Critical Care, 2018, 47, 15-20.	2.2	5
466	Does intermittent pneumatic compression PREVENT deep vein thrombosis in the ICU?. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 303-304.	1.4	5
467	There is no fire without smoke! Pathophysiology and treatment of inhalational injury in burns: A narrative review. Anaesthesia and Intensive Care, 2020, 48, 114-122.	0.7	5
468	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. International Journal of Antimicrobial Agents, 2021, 58, 106431.	2.5	5

#	Article	IF	CITATIONS
469	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Internal Medicine Journal, 2010, , .	0.8	5
470	Ventriculitis: Infection or Inflammation. Antibiotics, 2021, 10, 1246.	3.7	5
471	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	5
472	Accidental Intra-Arterial Adrenaline Administration. Anaesthesia and Intensive Care, 1995, 23, 488-489.	0.7	4
473	Emergency Percutaneous Balloon Mitral Valvotomy in a Patient With Septic Shock. Chest, 1995, 108, 570-572.	0.8	4
474	Preventive Strategies for Ventilator Associated Pneumonia. Current Respiratory Medicine Reviews, 2010, 6, 238-252.	0.2	4
475	Can Learning to Sustain Life be BASIC? Teaching for the Initial Management of the Critically III in Australia and New Zealand. Anaesthesia and Intensive Care, 2010, 38, 1043-1051.	0.7	4
476	Augmented renal clearance in traumatic brain injury. Critical Care, 2010, 14, P521.	5.8	4
477	Antibiotic prescription for respiratory tract infections in ventilated patients: where are we heading?. Intensive Care Medicine, 2013, 39, 1644-1646.	8.2	4
478	Antibiotic administration in the critically ill - in need of intensive care!. South African Medical Journal, 2015, 105, 357.	0.6	4
479	"Not out of the woodsâ€â€"a wife's perspective: bedside communication. Intensive Care Medicine, 2016, 42, 446-447.	8.2	4
480	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2018, 91, 69-76.	1.8	4
481	Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. Chemotherapy, 2019, 64, 115-118.	1.6	4
482	Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. Chemotherapy, 2019, 64, 173-176.	1.6	4
483	Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. International Journal of Antimicrobial Agents, 2020, 56, 106058.	2.5	4
484	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
485	Antimicrobial de-escalation is part of appropriate antibiotic usage in ICU. Intensive Care Medicine, 2020, 46, 1039-1042.	8.2	4
486	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, e0230720.	3.2	4

#	Article	IF	CITATIONS
487	Global personalization of antibiotic therapy in critically ill patients. Expert Review of Precision Medicine and Drug Development, 2021, 6, 87-93.	0.7	4
488	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane–tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. Clinical Chemistry and Laboratory Medicine, 2021, 59, 921-933.	2.3	4
489	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically III Patients in a Dynamic Infection Model. Antibiotics, 2022, 11, 101.	3.7	4
490	Renal replacement therapy for the critically illprecarious progress. Part II. Technical aspects and clinical application. South African Journal of Surgery, 1993, 31, 147-51.	0.2	4
491	Renal replacement therapy for the critically illprecarious progress. Part I. Definitions and physiological aspects. South African Journal of Surgery, 1993, 31, 114-20.	0.2	4
492	Population Pharmacokinetics of Intraperitoneal Gentamicin and the Impact of Varying Dwell Times on Pharmacodynamic Target Attainment in Patients with Acute Peritonitis Undergoing Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0167921.	3.2	4
493	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	4
494	The Microcirculation, Regional Blood Flow and Tissue Oxygenation: Will New Technologies Drive New Resuscitation Goals?. Anaesthesia and Intensive Care, 2009, 37, 700-702.	0.7	3
495	Midazolam Metabolism: Implications for Individualised Dosing?. Journal of Pharmacy Practice and Research, 2009, 39, 198-201.	0.8	3
496	Blood Culture Collection in Patients with Acute Kidney Injury Receiving Renal Replacement Therapy: An Observational Study. Anaesthesia and Intensive Care, 2012, 40, 813-819.	0.7	3
497	Anaesthetists' Experiences with the Early Labour Epidural Recommendation for Obese Parturients: A Qualitative Study. Anaesthesia and Intensive Care, 2016, 44, 620-627.	0.7	3
498	Pyroglutamate (5-oxoproline) measured with hydrophilic interaction chromatography (HILIC) tandem mass spectrometry in acutely ill patients. Clinica Chimica Acta, 2017, 466, 72-77.	1.1	3
499	Ceftriaxone dosing in patients admitted from the emergency department with sepsis. European Journal of Clinical Pharmacology, 2021, 77, 207-214.	1.9	3
500	A Loading Micafungin Dose in Critically III Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. Therapeutic Drug Monitoring, 2021, 43, 747-755.	2.0	3
501	Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 479-485.	1.6	3
502	Development and validation of a critical care patient classification system. American Journal of Critical Care, 1996, 5, 282-288.	1.6	3
503	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance. , 2010, , 495-506.		3
504	Epidemiology and Microbiology of Severe Communityâ€Acquired Pneumonia in Central Australia: A Retrospective Study. Internal Medicine Journal, 2020, , .	0.8	3

#	Article	IF	CITATIONS
505	A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2013, 15, 179-85.	0.1	3
506	Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study. Antibiotics, 2021, 10, 1559.	3.7	3
507	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. Clinical Pharmacokinetics, 2022, 61, 673-686.	3.5	3
508	Malignant astrocytoma of the cervico-medullary junction masquerading as Guillain-Barre syndrome Postgraduate Medical Journal, 1994, 70, 499-502.	1.8	2
509	Acute Respiratory Distress in a Bleomycin Primed Patient: A New Use for Nitric Oxide. Anaesthesia and Intensive Care, 2007, 35, 86-90.	0.7	2
510	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. BMJ Open, 2013, 3, e003511.	1.9	2
511	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	5.8	2
512	Antibiotic dose optimization in critically ill patients. Medicina Intensiva (English Edition), 2015, 39, 563-572.	0.2	2
513	In 2035, will all bacteria be multidrug-resistant? No. Intensive Care Medicine, 2016, 42, 2017-2020.	8.2	2
514	Are new gentamicin dosing guidelines suitable for achieving target concentrations in patients with sepsis and septic shock?. Anaesthesia, Critical Care & Pain Medicine, 2016, 35, 311-312.	1.4	2
515	The Statistical Curriculum Within Randomized Controlled Trials in Critical Illness*. Critical Care Medicine, 2018, 46, 1985-1990.	0.9	2
516	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. International Journal of Antimicrobial Agents, 2019, 54, 351-355.	2.5	2
517	Antimicrobial Resistance: We Must Pursue a Collaborative, Global Approach and Use a "One Health― Approach. Antibiotics, 2019, 8, 237.	3.7	2
518	A narrative review on antimicrobial therapy in septic shock: updates and controversies. Current Opinion in Anaesthesiology, 2021, 34, 92-98.	2.0	2
519	Ventilation practices in burn patients—an international prospective observational cohort study. Burns and Trauma, 2021, 9, tkab034.	4.9	2
520	Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa. Drugs in R and D, 2021, 21, 203-215.	2.2	2
521	Lorazepam challenge test for catatonia. EMA - Emergency Medicine Australasia, 2021, 33, 763-764.	1.1	2
522	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. Analytical and Bioanalytical Chemistry, 2021, 413, 4483-4491.	3.7	2

#	Article	IF	CITATIONS
523	Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115329.	1.8	2
524	Dose Adjustment and Pharmacodynamic Considerations for Antibiotics in Severe Sepsis and Septic Shock. , 2008, , 97-136.		2
525	A detailed feeding algorithm improves delivery of nutrition support in an intensive care unit. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2010, 12, 149-55.	0.1	2
526	A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samples—To Treat or Not to Treat? That Is the Question. Antibiotics, 2022, 11, 452.	3.7	2
527	Good Clinical Research Practice: What is it and is it Possible in the Intensive Care Unit?. Anaesthesia and Intensive Care, 1998, 26, 568-574.	0.7	1
528	Estimate of the Number of Patients Eligible for Treatment with Drotrecogin Alfa (Activated) Based on Differing International Indications: Post-hoc Analysis of an Inception Cohort Study in Australia and New Zealand. Anaesthesia and Intensive Care, 2006, 34, 184-190.	0.7	1
529	Continuous Infusion of Time-dependent Antibiotics. Clinical Pulmonary Medicine, 2008, 15, 167-172.	0.3	1
530	Optimizing Antibiotic Use in the Intensive Care Unit. Clinical Pulmonary Medicine, 2010, 17, 162-169.	0.3	1
531	Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). Journal of Antimicrobial Chemotherapy, 2010, 65, 2061-2061.	3.0	1
532	A novel molecular biomarker diagnostic for the early detection of sepsis. Critical Care, 2010, 14, P9.	5.8	1
533	A limited set of molecular biomarkers may provide superior diagnostic outcomes to procalcitonin in sepsis. Critical Care, 2012, 16, .	5.8	1
534	Sepsis Management. , 2012, , .		1
535	From the intensive care bed: we need to hear and listen. Intensive Care Medicine, 2015, 41, 921-922.	8.2	1
536	The authors reply. Critical Care Medicine, 2015, 43, e154-e155.	0.9	1
537	Bugs, genes, and the intensive care unit. Journal of Thoracic Disease, 2016, 8, E788-E790.	1.4	1
538	A validated UHPLC–MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. Biomedical Chromatography, 2017, 31, e4030.	1.7	1
539	Interpretation of Care Guidelines for Obese Women in Labor: Intergroup Language and Social Identity. Journal of Language and Social Psychology, 2017, 36, 388-414.	2.3	1
540	Is augmented renal clearance the Holy Grail of antibiotic therapy failure in ventilator-acquired pneumonia?. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 5-6.	1.4	1

#	Article	IF	CITATIONS
541	Re: †Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?' Pharmacokinetic/pharmacodynamic considerations. Clinical Microbiology and Infection, 2018, 24, 666-667.	6.0	1
542	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. Pharmacotherapy, 2020, 40, 713-717.	2.6	1
543	Reâ€expansion pulmonary oedema with Takotsubo cardiomyopathy: a rare complication of giant hepatic cyst drainage. ANZ Journal of Surgery, 2021, 91, 2524-2527.	0.7	1
544	Dose Adjustment and Pharmacokinetics of Antibiotics in Severe Sepsis and Septic Shock. , 2007, , 122-146.		1
545	Prehospital Care. , 2008, , 307-319.		1
546	Candida Pneumonia in Patients with Hematological Neoplasia. , 2011, , 349-356.		1
547	Antibiotic dosing in sustained low-efficiency daily dialysis (SLEDD): Basic concepts and dosing strategies. Journal of Critical Care, 2022, 67, 104-107.	2.2	1
548	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. International Journal of Antimicrobial Agents, 2022, 59, 106513.	2.5	1
549	Towards better ICU antibiotic dosing. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2000, 2, 282-9.	0.1	1
550	Use of neostigmine for acute colonic pseudo-obstruction in a patient receiving dexmedetomidine. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2016, 18, 59-61.	0.1	1
551	Survey of critical care practice in Australian and New Zealand burn referral centres. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 303-304.	0.1	1
552	Population Pharmacokinetic Model of Piperacillin in Critically III Patients and Describing Interethnic Variation Using External Validation. Antibiotics, 2022, 11, 434.	3.7	1
553	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. Journal of Antimicrobial Chemotherapy, 2022, 77, 2227-2237.	3.0	1
554	Failed Nasogastric Intubation in Undiagnosed Carcinoma of the Oesophagus. Anaesthesia and Intensive Care, 1995, 23, 370-372.	0.7	0
555	Does Intensive Care Always Have To Be Expensive Care?. Clinical Pulmonary Medicine, 1997, 4, 334-338.	0.3	0
556	Keeping relatives informed by the internet. Lancet, The, 1999, 354, 517-518.	13.7	0
557	Antibiotic Resistance in the Intensive Care Unit: A Primer in Bacteriology. Anaesthesia and Intensive Care, 2005, 33, 188-195.	0.7	0
558	Entrapped central venous catheter. British Journal of Anaesthesia, 2007, 98, 695.	3.4	0

#	Article	IF	CITATIONS
559	Dose matters: Dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. Critical Care Medicine, 2009, 37, 2491-2492.	0.9	Ο
560	Optimal Antibiotic Therapy in the Management of the Lung of the Critically III. Current Respiratory Medicine Reviews, 2010, 6, 253-263.	0.2	0
561	Respiratory Burns: A Clinical Review. Current Respiratory Medicine Reviews, 2010, 6, 285-291.	0.2	0
562	Importance of High Creatinine Clearance for Antibacterial Treatment in Sepsis. , 2012, , 171-197.		0
563	Reply to Soman et al. Clinical Infectious Diseases, 2013, 57, 323-324.	5.8	0
564	B-Type Natriuretic Peptide. A & A Case Reports, 2013, 1, 59-61.	0.7	0
565	The authors reply. Critical Care Medicine, 2014, 42, e675-e676.	0.9	0
566	The authors reply. Critical Care Medicine, 2014, 42, e602-e603.	0.9	0
567	The authors reply. Critical Care Medicine, 2015, 43, e101-e102.	0.9	0
568	The authors reply. Critical Care Medicine, 2018, 46, e725-e726.	0.9	0
569	A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy. Clinical Pharmacokinetics, 2019, 58, 263-270.	3.5	0
570	1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients. Open Forum Infectious Diseases, 2019, 6, S574-S575.	0.9	0
571	New guidelines for the management of severe thermal burns in the acute phase in adults and children: Is it time for a global surviving burn injury campaign (SBIC)?. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 195-196.	1.4	0
572	Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumoINSPIRE study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 59-66.	0.1	0
573	A Multicenter Observational Study Evaluating Outcomes Associated With Antibiotic Combination Versus Monotherapy in Patients With Septic Shock. , 2021, 3, e0383.		0
574	Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent Î <sup>2</sup> -lactam antibiotic infusion in critically ill patients with sepsis. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 273-284.	0.1	0
575	Prescription of Antimicrobial Agents in Patients Undergoing Continuous Renal Replacement Therapy. , 2007, , 147-158.		0

#	Article	IF	CITATIONS
577	Antibiotic Dosing in Critically III Patients. , 0, , 128-128.		0
578	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance. Yearbook of Intensive Care and Emergency Medicine, 2010, , 495-506.	0.1	0
579	Antibiotic Therapy of Pneumonia in Critical Care. Current Respiratory Medicine Reviews, 2012, 8, 228-238.	0.2	0
580	Principles of antibiotic use. , 2014, , 738-742.e1.		0
581	Performance of the Pediatric Risk of Mortality Score. Critical Care Medicine, 1997, 25, 717.	0.9	0
582	Vancomycin Resistance in Gram-Positive Cocci—Old Bugs, New Tricks, Confusing Terminology. Anaesthesia and Intensive Care, 1999, 27, 396-399.	0.7	0
583	Micafungin Population PK Analysis in Healthy and Septic Pigs: Can the Septic Porcine Model Predict the Micafungin PK in Septic Patients?. Pharmaceutical Research, 2021, 38, 1863-1871.	3.5	0
584	Randomised controlled trials: the long hard climb to the summit-is there another way in the 21st century?. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2014, 16, 87-9.	0.1	0
585	Use and Abuse of Antibiotics. , 0, , 128-136.		Ο